S. Africa group writes to USTR in support of Indian drugs

P. T. Jyothi Datta Mumbai | Updated on March 09, 2018 Published on July 25, 2013


As India’s intellectual property protection policy comes under intense criticism in the United States — a pro-health group, South Africa’s Treatment Action Campaign, has come out in support of the Indian generic drugs industry.

In an open letter to US Trade Representative Ambassador Michael Froman, TAC expressed its concern at the “mounting US pressure” on India’s generic medicines industry.

The letter comes at a time when US Vice-President Joe Biden is in India to improve trade ties between the two countries.

In its letter, the TAC said that it specifically objected “the placement of India on the US ‘Special 301 Watch List’ over objections to the country's intellectual property system, as well as subsequent condemnation from Members of Congress stemming from US pharmaceutical industry pressure, and attempts by a group of US commercial businesses (under the banner of ‘Alliance for Fair Trade with India’) to influence Vice-President Biden’s current meetings in India.”

India’s generic manufacturing industry has become as an essential source of affordable medicines, producing over 80 per cent of medicines, and as many as 90 per cent of paediatric medicines are used in the developing world, the letter said.

Landmark judgments

Following the landmark patent cases on cancer drugs Glivec and Nexavar, there has been pressure on India to increase its intellectual property protection despite the fact that in both instances India acted in compliance with the WTO’s agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), the letter said.

Through strict patentability criteria outlined in Section 3(d) of the Indian Patents Act which grants new patents only to medicines with enhanced efficacy, India has avoided granting excessive monopolies for secondary use, combinations or mere minor incremental changes.

It would be hypocritical of the US Government to condemn this legal action after the Bush Administration threatened to utilise similar flexibility to produce a stockpile of ciprofloxacin (Cipro) — enough to treat 10 million people in the face of an Anthrax scare in 2001[9], the letter said.

In South Africa, the combination of low patentability criteria and the lack of an effective patent examination system have lead to excessive patenting in the country, maintaining artificially high prices on newer, more effective medicines and blocking generic equivalents from entering the market. Restrictions on India would amplify such problems on a disastrous global scale, the latter pointed out.

“At a time of budget deficits and funding cuts, additional costs must not be incurred to restrict access to life-saving medicines that millions of people rely on around the world. We urge the US Government to stand strong against pressure from the pharmaceutical lobby and actively support and applaud enabling policies that ensure that India, the ‘pharmacy of the developing world’, can continue to produce affordable generic medicines that so many of us rely on to stay alive,” TAC Chairman Anele Yawa said in the open letter.


Published on July 25, 2013

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.